Aptean Acquires GQ Life Sciences
News Oct 05, 2016
Aptean announced the acquisition of GQ Life Sciences, Inc.
“The acquisition of GQ Life Sciences expands our ability to provide vertically-focused mission critical enterprise solutions by entering the Life Sciences and Big Data market s where we see significant growth opportunities,” said Kim Eaton, Aptean CEO. “GQ Life Sciences leverages its deep expertise in biology, genomics, and semantics to deliver a best -¬‐ in -¬‐ class patent search solution, fueled by the world’s largest database of biological sequences. The solution is used daily by research professionals around the globe to provide insight into emerging inventions and enable their future innovations.”
“As a part of Aptean, GQ Life Sciences will ha ve the opportunity to expand the development of our proprietary search algorithms and data base model to create richer search options and deeper insights for the patent searcher and scientific researcher,” said Richard Resnick, GQ Life Science CEO. “We look forward to utilizing Aptean’s global reach and operational efficiencies to expand our business while continuing to provide the unmatched data and services our customers know and trust to mitigate risk and protect their intellectual property.”
GQ Life Sciences’ flagship product, GenomeQuest, provides researchers with the ability to search for biological sequences across 815k worldwide patents (or over 345m+ sequences). GQ Life Sciences also recently launched LifeQuest, a specialized keyword search tool, which provides a wider range of users the ability to scan a dedicated database of more than 15 million Life Science patents. Since 1999 GQ Life Sciences has built a strong reputation in the Life Sciences industry, now serving nine of the top ten pharmaceutical companies, all five top agrochemical and seed companies, biotech companies, law firms, diagnostic labs, and patent offices around the world.
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.